Anti-senescence compounds and uses thereof
AssigneeCleara Biotech B.V.
InventorsPeterus Leonardus Josephus De Keizer, Michael Teifel, Tobias Madl, Benjamin Michel Rene Bourgeois, Emil Spreitzer, Yvonne Marie Angell, Marjolein Petronella Baar
Life of this patent
Estimating the term…
Abstract
The present invention relates to improved compounds for use in the treatment of diseases or conditions where the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial, for example cancer. The invention also relates to methods of treating an individual suffering, or suspected of suffering, from a disease or condition wherein the removal of senescent cells, scarred cells, and/or cancerous cells is beneficial.
Claims6
A peptide comprising an amino acid sequence selected from the group consisting of
- i)
- (SEQ ID NO:
- 7)
- LTLRKEASSEIAQSILDAYSQNGWANRRSSCKRP,
- (SEQ ID NO:
- 8)
- LTLRKKASSKIAQSILDAFSQNGWANRRSSCKRP,
- (SEQ ID NO:
- 10)
- RKKASSKIAQSILDAFSQNGWANRRSSCKRP,
- (SEQ ID NO:
- 11)
- RKKASSKIAAAILDAFSQNGWANRRSSCKRP,
- (SEQ ID NO:
- 12)
- RKKASSKIAAAILDAFSQNAWANRRSSCKRP,
- (SEQ ID NO:
- 13)
- RKKASSKIAAAILDAFSQNWRRKR,
- (SEQ ID NO:
- 14)
- RKKASSKIEAAILDAFSQNWRRKR,
- (SEQ ID NO:
- 15)
- RKKASSKIAAEILDAFSQNWRRKR,
- (SEQ ID NO:
- 16)
- RKKASSKIEAEILDAFSQNWRRKR,
- (SEQ ID NO:
- 17)
- RKKSKIAAAILDAFSQNWRRKR,
- (SEQ ID NO:
- 18)
- RKKSKIEAEILDAFSQNWRRKR,
- (SEQ ID NO:
- 19)
- AKIAAAILDAFSQNWRRKR,
- (SEQ ID NO:
- 20)
- AKIEAAILDAFSQNWRRKR,
- (SEQ ID NO:
- 22)
- RKKASSKIAAAILDAFSQNGWANRRSSCKRPPPRRRQRRKKRG,
- (SEQ ID NO:
- 23)
- RKKASSKIAAAILDAFSQNAWANRRSSCKRPPPRRRQRRKKRA,
- (SEQ ID NO:
- 24)
- RKKASSKIAAAILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 25)
- RKKASSKIEAAILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 26)
- RKKASSKIAAEILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 27)
- RKKASSKIEAEILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 28)
- RKKSKIAAAILDAFSQNWRRKRRRRQRRKKRG,
- (SEQ ID NO:
- 29)
- RKKSKIEAEILDAFSQNWRRKRRRRQRRKKRG,
- (SEQ ID NO:
- 30)
- AKIAAAILDAFSQNWRRKRRRRQRRKKRG,
- (SEQ ID NO:
- 31)
- AKIEAAILDAFSQNWRRKRRRRQRRKKRG,
- (SEQ ID NO:
- 53)
- RKKASSKIEAEILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 54)
- RKKSKIEAEILDAFSQNWRKRRRRQRRKKRG,
- (SEQ ID NO:
- 55)
- AKIEAAILDAFSQNWRKRRRRQRRKKRG,
- (SEQ ID NO:
- 56)
- AKIEAEILDAFSQNWRKRRRRQRRKKRG,
- (SEQ ID NO:
- 57)
- AKIEAAILDEFSQNWRKRRRRQRRKKRG,
- (SEQ ID NO:
- 58)
- RKKASJKIAJAILDAFSQNWRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 59)
- RKKASSKIAAAZLDAFSQNAWANRRSSCKRPPPRRRQRRKKRA,
- (SEQ ID NO:
- 60)
- AKIEAAILDAFSQNBRKRRRRQRRKKRG,
- (SEQ ID NO:
- 61)
- AKIEAEILEAFSQNBRKRRRRQRRKKRG,
- (SEQ ID NO:
- 62)
- AKIEAAZLDAFSQNBRKRRRRQRRKKRG,
- (SEQ ID NO:
- 63)
- RKKASSKIEAEILDAFSQNBRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 64)
- RKKASSKIEAEZLDAFSQNBRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 65)
- RKKASSKIEAEIZDAFSQNBRRKRPPRRRQRRKKRG,
- (SEQ ID NO:
- 67)
- RKKSKIAAAILDAFSQNWRKRRRRQRRKKRG, and
- (SEQ ID NO:
- 68)
- RKKASSKIEAAILDAFSQNWRRKRPPRRRQRRKKRG,
- wherein Z is Cyclo-Hexyl-Alanine, and B is 2-Methyl-Tryptophan,
- and pharmaceutically acceptable salts thereof;
- and
- ii) a peptide according to i) comprising at least 80% D-amino acids, and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.